Characterization of MPL-nanoliposomes with Her2/neu derived peptide GP2 as vaccine against breast cancer in BALB/c mice TUBO xenograft model

سال انتشار: 1396
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 547

متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

NTNM01_042

تاریخ نمایه سازی: 7 اسفند 1396

چکیده مقاله:

HER2/neu is an immunogenic protein eliciting both humoral and cellular immune responses in patients with HER2/neu-positive tumors. The goal of this study was to induce and enhance an effective cytotoxic T lymphocyte (CTL) response against peptide Gp2 derived from HER 2/neu oncogene and MPL adjuvant by employing the potential benefit of liposomes as a co-delivery vehicle. MPL have been shown to have potent adjuvant activity for a wide range of antigens. In this study, different groups of mice were subcutaneously vaccinated with five formulations containing DMPC/DMPG/Chol (30:4:6) with or without DOPE, MPL (25 µg per mouse) and peptide conjugated to - DSPE- mPEG2000- Maleimide lipid and also Hepes/sucrose buffer as control. Released amount of IFN-γ were determined by flow cytometric analysis, ELISpot kits, Intracellular cytokine assay and RT-PCR was used to identify IFN-γ and IL-4 producing cells. Consequently, mice immunized with lip-DOPE-MPL-GP2 formulation had the most released IFN-γ and the highest CTL responses followed by Lip-Gp2 and GP2 formulation group

نویسندگان

a Razazan

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

m Ghahremani

Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

j Behravan

Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

a Arab

Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran